New Alzheimer’s Drug Doesn’t Show Net Benefit, Report Finds
April 19, 2023
(Axios) – Eisai and Biogen’s new Alzheimer’s drug lecanemab doesn’t show a net health benefit over current treatment options and, at its current price, represents low long-term value for the money, the Institute for Clinical and Economic Review said in a report on Monday. Why it matters: The findings cast doubts on the first treatment shown to delay cognitive decline from Alzheimer’s — which affects over six million people in the U.S. (Read More)